GlassScriptPhysician profile
Vanosia Shablee Faison
NPI 1023199817
$3,287.44
in general payments reported to CMS, 2019-2025
31 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.23 · 2020: $152 · 2021: $686 · 2022: $1,182 · 2023: $557 · 2024: $425 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.34 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.16 | 2021-2024 | |
| Novo Nordisk INC | $416.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $330.33 | 2019-2024 | |
| Lilly USA, LLC | $252.66 | 2020-2025 | Mounjaro |
| Abbott Laboratories | $238.66 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $203.52 | 2020-2025 | Repatha, Krystexxa |
| Astellas Pharma US INC | $200.70 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.58 | 2020-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $150.81 | 2022 | |
| Neurocrine Biosciences, INC. | $138.90 | 2022-2023 | Ingrezza |
| Glaxosmithkline, LLC. | $93.44 | 2019-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $74.34 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $60.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $52.00 | 2022-2023 | Rexulti |
| Dexcom, INC. | $51.76 | 2021-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.07 | 2023-2024 | Cologuard Collection Kit |
| Intuitive Surgical, INC. | $44.93 | 2025 | |
| Redhill Biopharma INC. | $37.50 | 2021 | |
| Mylan Specialty L.P. | $35.97 | 2021-2022 | |
| Amarin Pharma, INC. | $33.77 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $29.28 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.73 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.23 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.30 | 2022 | |
| Akcea Therapeutics, INC. | $18.06 | 2021 | |
| Boston Scientific Corporation | $16.62 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.86 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.17 | 2021 | |
| Daiichi Sankyo INC. | $14.05 | 2021 | |
| Ibsa Pharma INC. | $13.93 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanosia Faison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.